We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
License and Collaboration Agreement was signed between OliX and Théa for OLX301A program, a novel treatment for dry and wet age-related macular degeneration (AMD).